Incyte Corporation (INCY)
Largest Insider Buys in Sector
INCY Stock Price History Chart
INCY Stock Performance
About Incyte Corporation
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its …
Insider Activity of Incyte Corporation
Over the last 12 months, insiders at Incyte Corporation have bought $0 and sold $4.77M worth of Incyte Corporation stock.
On average, over the past 5 years, insiders at Incyte Corporation have bought $86.42M and sold $18.74M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 84 shares for transaction amount of $6,044 was made by BAKER FELIX () on 2022‑03‑08.
List of Insider Buy and Sell Transactions, Incyte Corporation
| 2024-09-13 | Sale | Principal Accounting Officer | 382 0.0002% | $63.37 | $24,207 | +4.37% | ||
| 2024-09-12 | Sale | EVP, General Manager, Europe | 8,450 0.0043% | $62.36 | $526,948 | +4.62% | ||
| 2024-09-12 | Sale | Principal Accounting Officer | 572 0.0003% | $62.94 | $36,002 | +4.62% | ||
| 2024-08-12 | Sale | EVP & Chief Medical Officer | 11,608 0.006% | $60.63 | $703,793 | +7.58% | ||
| 2024-07-25 | Sale | EVP, GMAPPS | 15,571 0.0071% | $70.00 | $1.09M | -4.26% | ||
| 2024-07-16 | Sale | EVP & General Manager US | 1,306 0.0006% | $64.19 | $83,832 | +2.56% | ||
| 2024-07-09 | Sale | EVP & General Manager US | 8,148 0.0035% | $60.00 | $488,880 | 0.00% | ||
| 2024-06-12 | Sale | EVP & General Manager US | 19,164 0.0086% | $60.00 | $1.15M | +8.94% | ||
| 2024-06-06 | Sale | Principal Accounting Officer | 1,093 0.0005% | $58.91 | $64,389 | +11.61% | ||
| 2024-01-03 | Sale | EVP & Chief Medical Officer | 7,365 0.0033% | $65.51 | $482,481 | -8.17% | ||
| 2024-01-02 | Sale | EVP, GMAPPS | 657 0.0003% | $65.00 | $42,705 | -7.38% | ||
| 2023-12-13 | Sale | Principal Accounting Officer | 1,067 0.0005% | $62.37 | $66,549 | -5.45% | ||
| 2023-12-12 | Sale | Principal Accounting Officer | 210 <0.0001% | $57.36 | $12,046 | -1.99% | ||
| 2023-09-01 | Sale | EVP, Human Resources | 8,449 0.0038% | $65.13 | $550,283 | -9.49% | ||
| 2023-08-01 | Sale | EVP & Chief Medical Officer | 21,511 0.0096% | $63.28 | $1.36M | -7.87% | ||
| 2023-01-31 | Sale | EVP & General Counsel | 802 0.0004% | $84.06 | $67,416 | -25.80% | ||
| 2023-01-30 | Sale | EVP & General Counsel | 35,212 0.016% | $84.76 | $2.98M | -24.44% | ||
| 2023-01-26 | Sale | EVP & Chief Scientific Officer | 2,419 0.0011% | $85.00 | $205,615 | -26.33% | ||
| 2023-01-26 | Sale | EVP, GMAPPS | 7,000 0.0031% | $85.00 | $595,000 | -26.33% | ||
| 2023-01-04 | Sale | EVP & Chief Medical Officer | 28,399 0.0129% | $79.78 | $2.27M | -19.21% |
Insider Historical Profitability
| BAKER BROS. ADVISORS LP | 33039604 17.1501% | $81.46 | 11 | 0 | +3.8% | |
| BAKER JULIAN | director | 19757285 10.2555% | $81.46 | 8 | 0 | +17.75% |
| Baker Brothers Life Sciences Capital (GP), LLC | director, 10 percent owner | 12430783 6.4525% | $81.46 | 51 | 5 | +21.96% |
| Baker Biotech Capital (GP), LLC | director, 10 percent owner | 2933021 1.5225% | $81.46 | 43 | 5 | +21.05% |
| BAKER FELIX | 2926657 1.5192% | $81.46 | 1 | 0 | +8.15% |
Institutional Investor Ownership
| Baker Bros Advisors LP | $2.06B | 16.11 | 36.18M | +<0.01% | +$30,934.71 | 14.8 | |
| BlackRock | $1.32B | 10.35 | 23.24M | -4.35% | -$60.25M | 0.03 | |
| The Vanguard Group | $1.29B | 10.12 | 22.72M | +0.87% | +$11.19M | 0.02 | |
| Dodge & Cox | $878.25M | 6.87 | 15.42M | -4.19% | -$38.42M | 0.51 | |
| State Street | $563.98M | 4.41 | 9.9M | -2.18% | -$12.57M | 0.02 |